PTGX NASDAQ
Credit Risk of going bust: lower than 96% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down more than 99.9%), Protagonist Therapeutics, Inc. would be worth roughly what it owes.
Total debt $9.2M against a stock market value of $9.13B.
Distance to default 20.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.4M (short-term plus half of long-term), stock volatility 39.8%; Altman Z'' 25.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Newark, CA 94560
US
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Ali Asif | M-Exempt | 9,229 | $38.98 | 2026-09-30 |
| Ali Asif | S-Sale | 12,595 | $141.77 | 2026-09-30 |
| Ali Asif | S-Sale | 46,034 | $141.78 | 2026-09-30 |
| Ali Asif | M-Exempt | 9,229 | $38.98 | 2026-09-30 |
| PATEL DINESH V PH D | S-Sale | 7,278 | $144.10 | 2026-09-10 |